T Lymphocytes (LT) Expressing iCASP9 and ΔCD19 in Allogeneic Haematopoietic Transplantation.

Graft Versus Host Disease Clinical Trial

— Side_by_Cide  

Official title:

Use of Genetically Modified T-lymphocytes Expressing the Inducible Human Caspase 9 Gene (iCASP9) and the Selection Gene ΔCD19 in Allogeneic Haematopoietic Transplantation.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02849886
• Other study ID #: N/2000/39-B
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: April 10, 2019
• Est. completion date: December 2021

Study information

• Verified date: July 2020
• Source: Centre Hospitalier Universitaire de Besancon
• Contact: Eric DECONINCK, MD, PhD, HDR
• Phone: +33381668404
• Email: edeconinck[@]chu-besancon.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study evaluates the frequency of occurrence, severity, and response to treatment by a chemical agent, notably the dimerizer AP1903 (Bellicum Pharmaceuticals compagny), in the case of acute Graft versus Host Disease (aGvHD) occurring after the administration of T-lymphocytes expressing iCASP9 and concomitantly to a bone marrow graft depleted in B- and T-lymphocytes

Description:

Haematopoietic transplantation may result in serious complications, notably graft versus host disease (GvHD).

T-lymphocyte depletion of the bone marrow graft is able to prevent GvHD, while increasing the risk of rejection and reducing the antileukaemic effect of the graft (graft versus leukaemia, GvL). In a previous study, the investigators showed that the ex vivo transfer of the Herpes simplex thymidine kinase suicide gene (HSV-TK) into the graft's T lymphocytes prior to reinjection was not associated with immediate toxicity, while allowing for the prolonged recirculation of genetically modified cells (GMC) and control of induced GvHD by ganciclovir (GCV). In addition, this study revealed the existence of GMC resistant to GCV, an immunodeficiency of transduced cells, as well as an increased risk of Epstein-Barr virus (EBV)-induced lymphoproliferative disease. To overcome these difficulties, investigators improved the methodology of producing GMC by using a new vector (pMSCV-iCASP9-2A-ΔCD19) whose susceptibility gene was of human origin and associated with a human surface marker (non-functional) enabling the cell selection process. Moreover, the demonstration that the induced GvHD in this setting could be controlled by the administration of GCV alone led to significantly increase the number of genetically modified T-lymphocytes administered and omit cyclosporin prophylaxis of GvHD.

This phase I study will include 12 patients and will be conducted according the dose escalation method (2.10e6, 5.10e6 and 10.10e6 GMC / kg respectively for levels I, II & III). GMC will be prepared in the Cell and Tissue Engineering Laboratory (advanced therapy medicinal products departement) of the french Blood center (EFS) in Besançon, France, and sent to the transplantation department.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 12
• Est. completion date: December 2021
• Est. primary completion date: December 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 55 Years

Eligibility

Inclusion Criteria:

• Adult patients aged =55 years (40< age =55 years);

• Patients who are candidates for myeloablative allogeneic bone marrow transplants: de novo or secondary acute lymphoblastic leukaemia (ALL) and acute myeloblastic leukaemia (AML) in complete remission (CR) =1; chronic myeloid leukaemia (CML) in chronic phase or in escape from tyrosine kinase inhibitors; myelodysplastic syndrome (MDS) with int-2 or high International Prognostic Scoring System (IPSS score, with medullary blastosis >10%); chemosensitive malignant non-Hodgkin's lymphoma (MNHL) in CR or partial remission (PR) >2 ; chemosensitive Hodgkin's disease in CR or PR >2 ; chemosensitive chronic lymphoid leukaemia (CLL) in CR or PR >2; chemosensitive myeloma in CR or PR =2;

• At high risk for GvHD: the risk for GvHD is considered high and the patient thus eligible for the study, if the receiver is >40 years, or if the donor is a woman and the receiver a man, regardless their age;

• Karnofsky index >70% or World Health Organization (WHO) index =2;

• Stable clinical conditions and life expectancy >3 months;

• Absence of organic disease contraindicating the transplantation

• Availability of a genotypically identical donor, aged >18 years, having given consent, and presenting no contraindications to bone marrow donation under general anaesthesia and to the required apheresis procedures;

• Written informed consent of the donor and patient.

Exclusion Criteria:

• Age <40 years or > 55 years

• Organic disease contraindicating the utilisation of myeloablative conditioning

• History of allogeneic Hematological Stem Cell Transplantation (HSCT);

• History of autologous HSCT <1 year prior to the date for the scheduled allogeneic HSCT;

• Neurological location of the haemopathy justifying the transplantation;

• Pregnant or breastfeeding woman;

• Positive HIV serology;

• Positive hepatitis B or hepatitis C serology (except for post-vaccinal hepatitis B status);

• Absence of informed consent from the receiver or donor;

• Inability to adhere to the protocol instructions.

Related Conditions & MeSH terms

• Graft Versus Host Disease
• Graft vs Host Disease
• Hematologic Neoplasms
• Hematological Malignancies

Intervention

Drug:
• T lymphocytes iCASP9 ?CD19
Intravenous injection of the T lymphocytes armed with the iCASP9 suicide gene
• Dimerizer drug AP1903
AP1903 drug will be administrated at a dose of 0.4 mg/kg by intravenous route in the two following cases: Acute Grade =II or symptomatic Grade I GvHD justifying systemic immunosuppression therapy; Grade =3 toxicity attributable to GMC.

Locations

Country	Name	City	State
France	CHU Jean Minjoz	Besançon

Sponsors (3)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Besancon	Bellicum Pharmaceuticals, Etablissement Français du Sang

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	GvHD response to Dimerizer AP1903	Disappearance of clinical signs of GvHD	72 hours after administration of Dimerizer AP1903
Secondary	Haematopoietic reconstitution (Blood)	Full Blood count and Blood Cell phenotyping (T & B Lymphocytes, Natural Killers cells (NK), polynuclear cells...); Hematopoietic reconstitution will be assessed when % of Blood cells reach normal account values.	1 month, 3 months, 6 months, and 1 year
Secondary	Haematopoietic engraftment (bone marrow)	Bone marrow smear analysis.; Haematopoietic engraftment will be assessed when proportion of marrow cells reach normal account values.	1 month, 3 months, 6 months, and 1 year
Secondary	Haematopoietic engraftment (chimerism)	Chimerism Analysis by quantitative mesurement (mesure of % of Donor & recipient cells); Full chimerism will be assessed when chimerim will reach 100% of donor profile.	1 month, 3 months, 6 months, and 1 year
Secondary	Infections post Transplantation	Monitoring of Infections post-transplantation will be studied by analysis of frequency of infection's events.; (number of infection's events by patients and/or frequency)	1 month, 3 months, 6 months, and 1 year
Secondary	GvL effect	Molecular residual disease (MRD) analysis of biological markers of the initial hematological disease either by molecular biology and/or flow cytometry.; GvL effect will be assessed by evaluation of decrease of initial tumoral load.	1 month, 3 months, 6 months, and 1 year